What is an FDA Complete Response Letter (CRL)?
The FDA's formal response that a drug cannot be approved in its current form — what it means, why stocks drop, and how to assess whether a resubmission will succeed.
The Short Answer
A Complete Response Letter (CRL) is a formal letter from the FDA to a drug company saying: "We cannot approve your application right now. Here is a list of problems you need to fix before we can approve it."
A CRL is not a permanent rejection. The company can fix the listed deficiencies and resubmit. But the path from CRL to approval typically takes 6–24 months and costs tens of millions of dollars — which is why the stock usually drops hard the day a CRL is announced.
The FDA issues CRLs across four distinct categories. The category matters enormously: a manufacturing CRL is much more fixable than a safety CRL, and the stock price reaction and resubmission probability reflect that difference.
The Four Types of CRL
1. CMC (Chemistry, Manufacturing, and Controls)
The most common type of CRL. The drug itself may work fine clinically, but the FDA has concerns about how it's manufactured — the facility hasn't been inspected or passed, there are quality control issues, the formulation needs changes, or the company hasn't demonstrated adequate shelf-life stability data.
Resubmission success rate: ~74%. The clinical case is already made — the company just needs to address manufacturing. Companies typically fix CMC issues by retooling their facility, switching contract manufacturers, or providing additional stability data. Timeline to resubmission: 6–18 months.
2. Clinical / Efficacy
The FDA isn't convinced the drug works well enough. This usually means the primary endpoint wasn't met with statistical significance, the patient population was too small, the trial design was flawed, or the treatment benefit doesn't outweigh the risk. This is the most damaging type of CRL for a stock price because it requires new clinical trials — which take years and hundreds of millions of dollars.
Resubmission success rate: ~44%. The company has to either run new trials or reanalyze existing data to address FDA's concerns. Timeline to resubmission: 12–48 months if additional trials are required. Many companies cannot survive this financially.
3. Safety
The FDA believes the drug's risks outweigh its benefits, or that the safety profile isn't adequately characterized. This is the rarest and most severe type. FDA may have seen unexpected adverse events in the clinical data, or post-market signals from similar drugs in the class.
Resubmission success rate: ~40%. The company may need to run additional long-term safety studies, modify the dosing regimen, or add a REMS (Risk Evaluation and Mitigation Strategy). Some drugs never get approved after a safety CRL.
4. Labeling
The FDA disagrees with how the company wants to describe the drug in its prescribing information — the indication language, contraindications, warnings, or black box text. This is typically the most benign type of CRL because it doesn't question the drug's clinical efficacy or safety.
Resubmission success rate: ~85%+. Labeling negotiations happen between the company's regulatory team and FDA reviewers. Often resolves in 3–6 months. Stock drops on labeling CRLs tend to be smaller than clinical or CMC CRLs.
Resubmission Success Rates by CRL Type
| CRL Type | Frequency | Resubmission Success | Typical Timeline | Stock Recovery |
|---|---|---|---|---|
| Labeling | ~15% of CRLs | ~85% | 3–6 months | Often partially recovers quickly |
| CMC / Manufacturing | ~35% of CRLs | ~74% | 6–18 months | Slow recovery; depends on cash |
| Clinical / Efficacy | ~35% of CRLs | ~44% | 12–48 months | Usually doesn't recover near-term |
| Safety | ~15% of CRLs | ~40% | 18–60 months | Often permanent impairment |
How Much Does a Stock Drop on a CRL?
The drop depends on three things: whether the CRL was expected, the market cap of the company, and the type of CRL. The general pattern:
Small-cap biotech (under $500M): 40–75% drop. Small-caps often have a single asset, and a CRL delays their only path to revenue by 1–3 years. If cash runway is short, a CRL can be existential.
Mid-cap biotech ($500M–$5B): 20–45% drop. More cash, more pipeline diversification, but still a major setback. Often accompanied by a secondary offering to fund the resubmission process.
Large-cap pharma ($5B+): 5–20% drop. Large companies absorb CRLs better because they have diversified revenue and deep balance sheets. The market prices in the probability that the drug eventually gets approved.
The Submarine Catalyst scanner's STN (Sell-The-News) Risk layer scores downside risk before every PDUFA event. A HIGH STN risk flag doesn't only mean "stock drops after approval" — it also reflects elevated binary risk in both directions. Drugs with HIGH STN risk have historically experienced severe downside whether the outcome was approval-with-disappointment OR a CRL. The model flagged REPL HIGH before the decision. The stock dropped 19.46% on the CRL.
Real Case Studies
Scanner PoA: 84% · Scanner STN Risk: HIGH
Outcome: ❌ CRL — FDA issued Complete Response Letter
Post-CRL move: −19.46%
CRL type: CMC/manufacturing (chemistry, manufacturing, and controls deficiency)
Analysis: The scanner's PoA model called 84% approval — a miss. The clinical data for vamorolone was strong; the CRL was a manufacturing issue, not an efficacy concern. Crucially, the STN HIGH flag was correct: the stock dropped hard regardless of the reason. The REPL CRL directly prompted an update to Submarine Catalyst's scoring model to add explicit CMC risk detection as a PoA penalty layer.
Scanner PoA: 77.5% · Scanner STN Risk: HIGH
Outcome: ✅ Approved
Post-approval move: −20% (sell-the-news)
Analysis: Approval on a resubmission after prior CRL. Unanimous AdCom. Gene therapy for 30 patients. TAM/Cap ratio 0.04x. The STN model correctly predicted the stock would drop even on approval. This illustrates why "not a CRL" doesn't mean "profitable trade."
How to Assess a CRL Before It Happens
The best time to think about CRL risk is before the PDUFA date — not after. Three signals that the scanner watches for:
1. Manufacturing complexity signals
SEC filings mentioning new facilities, contract manufacturer changes, scale-up challenges, or GMP compliance language in risk factors. These appear in 10-K and 10-Q filings 6–18 months before the PDUFA date and are the clearest leading indicator of a CMC CRL. The Submarine Catalyst EDGAR scanner checks for these automatically.
2. FDA communication signals
Review extensions (3-month extensions), major amendments, and complete response letter history (prior CRL on the same drug). These show up in company press releases and SEC 8-K filings. A 3-month review extension is not automatically bad — but it indicates FDA is asking questions about something.
3. Indication-specific CRL rates
Some disease areas have historically higher CRL rates than the overall average. Neuromuscular diseases (DMD, ALS, SMA), CNS conditions, and gene therapies all have higher-than-average CRL rates due to endpoint complexity, manufacturing challenges, and evolving FDA precedent. The scanner's PoA model now applies indication-specific CRL risk penalties.
What Happens After a CRL
The company has two choices: resubmit or withdraw the application. Almost all companies resubmit unless the CRL identified insurmountable clinical problems.
The resubmission is classified as Class 1 (minor issues, 2-month review) or Class 2 (substantial new data, 6-month review). The company discloses the classification in a press release, which tells you how long until the next PDUFA date.
From a trading perspective, CRL stocks often find a floor 3–6 months after the initial drop as the market begins pricing in the resubmission timeline. Traders who understand the CRL type and resubmission probability can identify whether the post-CRL price represents an opportunity or a value trap.
Frequently Asked Questions
Continue learning: How Institutions Trade PDUFA Events →
See the full track record including the REPL CRL: Track Record →
Access the Scanner — $29.99/monthPDUFA scanner · Buyout scanner · STN Risk scores · AI research tool · 870+ companies